Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) ...Middle East

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P

Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) )

Also on site :

• Greta Thunberg bizarrely claims she DIDN’T KNOW her ‘Freedom Flotilla’ crewmates had shown support for Hamas & Hezbollah
• Trump says reconciliation with Musk is possible in interview before Tesla boss’s apology
• Waste accumulation threatens health of al-Kashkiya residents in Deir Ezzor